Drug intelligence / Profile preview

Sanhua for injection

Development stage: Unknown
Lead developer: Tsinghua Yuanxing Pharmaceutical
Administration: Parenteral

Overview

**Sanhua for injection** is an investigational injectable traditional Chinese medicine product developed by Tsinghua Yuanxing Pharmaceutical for acute cerebral infarction. Its stated formulation combines notoginseng total saponins with breviscapine, an extract-derived flavonoid preparation. A randomized, blinded, multicenter Phase 2 study evaluated it in patients with acute cerebral infarction of the internal-carotid-territory large-artery-atherosclerosis subtype and traditional Chinese medicine blood-stasis-obstructing-collaterals syndrome; breviscapine injection, notoginseng total-saponin injection, and placebo were parallel controls. ([synapse.zhihuiya.com](https://synapse.zhihuiya.com/drug/79e423fb5e1e493aad165db1ce32c5a4))

Other names: Sanhuafen injection注射用三花粉针剂

Beyond the preview

Go deeper on Sanhua for injection.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanhua for injection.

Explore the full profile